Poll

A New Combination Proves Itself in Treatment for Type 2 Diabetes

Question 2. The rationale for combination therapy with SGLT2 inhibitor and a DPP-4 inhibitor is based on:

A. Increased bioavailability of both drugs when administered together.
B. Less glucose production in the presence of a DPP-4 inhibitor in response to the glucosuria produced by SGLT2 inhibition
C. Increased affinity of the SGLT2 inhibitor to its target in the renal tubule in the presence of a DPP-4 inhibitor.
D. None of the above
Related Videos
Rahul Aggarwal, MD | Credit: LinkedIn
Brendon Neuen, MBBS, PhD | Credit: X.com
HCPLive Five at ADA 2024 | Image Credit: HCPLive
Ralph DeFronzo, MD | Credit: UT San Antonio
Timothy Garvey, MD | Credit: University of Alabama at Birmingham
Alexandra Louise Møller, MS, PhD | Credit: LinkedIn
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Optimizing Diabetes Therapies with New Classifications
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Related Content
HCPLive Endocrinology Month in Review September 2024 thumbnail
October 6th 2024

Endocrinology Month in Review: September 2024

Patrick Campbell
Taher Modarressi, MD | Credit: X.com
October 3rd 2024

Don't Miss a Beat: Putting Evidence-Based Cardiometabolic Therapies into Practice, with Taher Modarressi, MD

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
September 18th 2024

FDA Clears Eversense 365, Marking First 1-Year CGM Option in Diabetes

Patrick Campbell
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
September 12th 2024

Diabetes Dialogue: Real-World Experience with the Dexcom Stelo

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
HCPLive Endocrinology Month In Review August 2024
September 10th 2024

Endocrinology Month in Review: August 2024

Patrick Campbell
Brendon Neuen, MBBS, PhD | Credit: X.com
September 1st 2024

Brendon Neuen, MBBS, PhD: Expanding Evidence of Combination Therapy with GLP-1 RAs and SGLT2 Inhibitors

Patrick Campbell
© 2024 MJH Life Sciences

All rights reserved.